{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:05:35Z","timestamp":1793048735253,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amyloidosis Research Consortium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Amyloid transthyretin (ATTR) amyloidosis with polyneuropathy (PN) is a progressive, debilitating, systemic disease wherein transthyretin protein misfolds to form amyloid, which is deposited in the endoneurium. ATTR amyloidosis with PN is the most serious hereditary polyneuropathy of adult onset. It arises from a hereditary mutation in the\n                    <jats:italic>TTR<\/jats:italic>\n                    gene and may involve the heart as well as other organs. It is critical to identify and diagnose the disease earlier because treatments are available to help slow the progression of neuropathy. Early diagnosis is complicated, however, because presentation may vary and family history is not always known. Symptoms may be mistakenly attributed to other diseases such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), idiopathic axonal polyneuropathy, lumbar spinal stenosis, and, more rarely, diabetic neuropathy and AL amyloidosis. In endemic countries (e.g., Portugal, Japan, Sweden, Brazil), ATTR amyloidosis with PN should be suspected in any patient who has length-dependent small-fiber PN with autonomic dysfunction and a family history of ATTR amyloidosis, unexplained weight loss, heart rhythm disorders, vitreous opacities, or renal abnormalities. In nonendemic countries, the disease may present as idiopathic rapidly progressive sensory motor axonal neuropathy or atypical CIDP with any of the above symptoms or with bilateral carpal tunnel syndrome, gait disorders, or cardiac hypertrophy. Diagnosis should include DNA testing, biopsy, and amyloid typing. Patients should be followed up every 6\u201312\u00a0months, depending on the severity of the disease and response to therapy. This review outlines detailed recommendations to improve the diagnosis of ATTR amyloidosis with PN.\n                  <\/jats:p>","DOI":"10.1007\/s00415-019-09688-0","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T07:02:43Z","timestamp":1578294163000},"page":"2109-2122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":271,"title":["Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-4108","authenticated-orcid":false,"given":"David","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Melo","family":"Beir\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole B.","family":"Suhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"issue":"7","key":"9688_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15(7):387\u2013404","journal-title":"Nat Rev Neurol"},{"key":"9688_CR2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, Stewart M, Fallet S, Amass L (2018) Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 57:829\u2013837","journal-title":"Muscle Nerve"},{"key":"9688_CR3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1172\/JCI111390","volume":"74","author":"MJ Saraiva","year":"1984","unstructured":"Saraiva MJ, Birken S, Costa PP, Goodman DS (1984) Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Investig 74:104\u2013119","journal-title":"J Clin Investig"},{"key":"9688_CR4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB (2015) Evolving landscape in the management of transthyretin amyloidosis. Ann Med 47:625\u2013638","journal-title":"Ann Med"},{"key":"9688_CR5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34:520\u2013528","journal-title":"Eur Heart J"},{"key":"9688_CR6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","volume":"20","author":"A Castano","year":"2015","unstructured":"Castano A, Drachman BM, Judge D, Maurer MS (2015) Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 20:163\u2013178","journal-title":"Heart Fail Rev"},{"key":"9688_CR7","unstructured":"Coutinho P, Martins da Silva A, Lopas LJ (1980) Forty years of experience with type 1 amyloid neuropathy. Review of 483 cases. In: Amyloid and amyloidosis. Excerpta Medica, Amsterdam, pp 88\u201398"},{"key":"9688_CR8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J, Kawanami T, Kato T, Yamamoto M, Sobue G (2012) Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 83:152\u2013158","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9688_CR9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"C Andrade","year":"1952","unstructured":"Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408\u2013427","journal-title":"Brain"},{"key":"9688_CR10","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, Obici L, Westermark P, Grateau G, Wechalekar AD (2014) Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 35:E2403\u20132412","journal-title":"Hum Mutat"},{"key":"9688_CR11","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, Grogan M, Kristen AV, Lousada I, Nativi-Nicolau J, Cristina Quarta C, Rapezzi C, Ruberg FL, Witteles R, Merlini G (2019) Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 12:e006075","journal-title":"Circ Heart Fail"},{"key":"9688_CR12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/14656566.2016.1145664","volume":"17","author":"D Adams","year":"2016","unstructured":"Adams D, Cauquil C, Labeyrie C, Beaudonnet G, Algalarrondo V, Theaudin M (2016) TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies. Expert Opin Pharmacother 17:791\u2013802","journal-title":"Expert Opin Pharmacother"},{"key":"9688_CR13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/WCO.0b013e328357bdf6","volume":"25","author":"D Adams","year":"2012","unstructured":"Adams D, Lozeron P, Lacroix C (2012) Amyloid neuropathies. Curr Opin Neurol 25:564\u2013572","journal-title":"Curr Opin Neurol"},{"key":"9688_CR14","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1136\/jmg.40.11.e120","volume":"40","author":"V Plante-Bordeneuve","year":"2003","unstructured":"Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, Said G, Bonaiti-Pellie C (2003) Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 40:e120","journal-title":"J Med Genet"},{"key":"9688_CR15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","volume":"15","author":"U Hellman","year":"2008","unstructured":"Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15:181\u2013186","journal-title":"Amyloid"},{"key":"9688_CR16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.neurol.2016.08.007","volume":"172","author":"D Adams","year":"2016","unstructured":"Adams D, Beaudonnet G, Adam C, Lacroix C, Theaudin M, Cauquil C, Labeyrie C (2016) Familial amyloid polyneuropathy: when does it stop to be asymptomatic and need a treatment? Rev Neurol (Paris) 172:645\u2013652","journal-title":"Rev Neurol (Paris)"},{"key":"9688_CR17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mus.25257","volume":"55","author":"T Coelho","year":"2017","unstructured":"Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR (2017) Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 55:323\u2013332","journal-title":"Muscle Nerve"},{"key":"9688_CR18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1756285612470192","volume":"6","author":"D Adams","year":"2013","unstructured":"Adams D (2013) Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord 6:129\u2013139","journal-title":"Ther Adv Neurol Disord"},{"key":"9688_CR19","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","volume":"59","author":"H Koike","year":"2002","unstructured":"Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G (2002) Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 59:1771\u20131776","journal-title":"Arch Neurol"},{"key":"9688_CR20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/13506129.2010.483114","volume":"17","author":"R Hornsten","year":"2010","unstructured":"Hornsten R, Pennlert J, Wiklund U, Lindqvist P, Jensen SM, Suhr OB (2010) Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 17:63\u201368","journal-title":"Amyloid"},{"key":"9688_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2350-11-130","volume":"11","author":"M Olsson","year":"2010","unstructured":"Olsson M, Norgren N, Obayashi K, Plante-Bordeneuve V, Suhr OB, Cederquist K, Jonasson J (2010) A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. BMC Med Genet 11:130","journal-title":"BMC Med Genet"},{"key":"9688_CR22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00415-017-8640-7","volume":"265","author":"T Yamashita","year":"2018","unstructured":"Yamashita T, Ueda M, Misumi Y, Masuda T, Nomura T, Tasaki M, Takamatsu K, Sasada K, Obayashi K, Matsui H, Ando Y (2018) Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol 265:134\u2013140","journal-title":"J Neurol"},{"key":"9688_CR23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","volume":"216","author":"E Ihse","year":"2008","unstructured":"Ihse E, Ybo A, Suhr OB, Lindqvist P, Backman C (2008) Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol 216:253\u2013261","journal-title":"J Pathol"},{"issue":"Suppl 1","key":"9688_CR24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/13506129.2012.685665","volume":"19","author":"D Adams","year":"2012","unstructured":"Adams D, Lozeron P, Theaudin M, Mincheva Z, Cauquil C, Adam C, Signate A, Vial C, Maisonobe T, Delmont E, Franques J, Vallat JM, Sole G, Pereon Y, Lacour A, Echaniz-Laguna A, Misrahi M, Lacroix C (2012) Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 19(Suppl 1):61\u201364","journal-title":"Amyloid"},{"key":"9688_CR25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, Merlini G, Obici L (2017) Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 88:457\u2013458","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9688_CR26","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","volume":"91","author":"P Lozeron","year":"2018","unstructured":"Lozeron P, Mariani LL, Dodet P, Beaudonnet G, Theaudin M, Adam C, Arnulf B, Adams D (2018) Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 91:e143\u2013e152","journal-title":"Neurology"},{"key":"9688_CR27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/ene.13845","volume":"26","author":"M Theaudin","year":"2019","unstructured":"Theaudin M, Lozeron P, Algalarrondo V, Lacroix C, Cauquil C, Labeyrie C, Slama MS, Adam C, Guiochon-Mantel A, Adams D, French FAPNSG (2019) Upper limb onset of hereditary transthyretin amyloidosis is common in non-endemic areas. Eur J Neurol 26:497\u2013e436","journal-title":"Eur J Neurol"},{"key":"9688_CR28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1529-8027.2011.00331.x","volume":"16","author":"M Cappellari","year":"2011","unstructured":"Cappellari M, Cavallaro T, Ferrarini M, Cabrini I, Taioli F, Ferrari S, Merlini G, Obici L, Briani C, Fabrizi GM (2011) Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 16:119\u2013129","journal-title":"J Peripher Nerv Syst"},{"key":"9688_CR29","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1212\/NXG.0000000000000018","volume":"1","author":"NA Goyal","year":"2015","unstructured":"Goyal NA, Mozaffar T (2015) Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy: An ALS mimicker. Neurol Genet 1:e18","journal-title":"Neurol Genet"},{"key":"9688_CR30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13506129.2011.565524","volume":"18","author":"H Koike","year":"2011","unstructured":"Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G (2011) Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 18:53\u201362","journal-title":"Amyloid"},{"key":"9688_CR31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.22229","volume":"45","author":"S Mathis","year":"2012","unstructured":"Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM (2012) Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 45:26\u201331","journal-title":"Muscle Nerve"},{"key":"9688_CR32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/13506129.2013.818535","volume":"20","author":"P Lozeron","year":"2013","unstructured":"Lozeron P, Lacroix C, Theaudin M, Richer A, Gugenheim M, Adams D, Misrahi M (2013) An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation. Amyloid 20:188\u2013192","journal-title":"Amyloid"},{"key":"9688_CR33","first-page":"542","volume":"86","author":"J Arpa Gutierrez","year":"1993","unstructured":"Arpa Gutierrez J, Morales C, Lara M, Munoz C, Garcia-Rojo M, Caminero A, Gutierrez M (1993) Type I familial amyloid polyneuropathy and pontine haemorrhage. Acta Neuropathol 86:542\u2013545","journal-title":"Acta Neuropathol"},{"key":"9688_CR34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jns.2009.04.015","volume":"284","author":"A Bersano","year":"2009","unstructured":"Bersano A, Del Bo R, Ballabio E, Cinnante C, Lanfranconi S, Comi GP, Baron P, Bresolin N, Candelise L (2009) Transthyretin Asn90 variant: amyloidogenic or non-amyloidogenic role. J Neurol Sci 284:113\u2013115","journal-title":"J Neurol Sci"},{"key":"9688_CR35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1440-1827.2001.01228.x","volume":"51","author":"N Sakashita","year":"2001","unstructured":"Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M (2001) Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int 51:476\u2013480","journal-title":"Pathol Int"},{"key":"9688_CR36","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.02.015","volume":"24","author":"F Salvi","year":"2015","unstructured":"Salvi F, Pastorelli F, Plasmati R, Morelli C, Rapezzi C, Bianchi A, Mascalchi M (2015) Brain microbleeds 12 years after orthotopic liver transplantation in Val30Met amyloidosis. J Stroke Cerebrovasc Dis 24:e149\u2013151","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"9688_CR37","first-page":"351","volume":"148","author":"MD Benson","year":"1996","unstructured":"Benson MD (1996) Leptomeningeal amyloid and variant transthyretins. Am J Pathol 148:351\u2013354","journal-title":"Am J Pathol"},{"key":"9688_CR38","first-page":"361","volume":"148","author":"R Vidal","year":"1996","unstructured":"Vidal R, Garzuly F, Budka H, Lalowski M, Linke RP, Brittig F, Frangione B, Wisniewski T (1996) Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G). Am J Pathol 148:361\u2013366","journal-title":"Am J Pathol"},{"key":"9688_CR39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/WNL.0b013e318248df18","volume":"78","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, Nakamura M, Jono H, Shono M, Asonuma K, Inomata Y, Uchino M (2012) Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 78:637\u2013643","journal-title":"Neurology"},{"key":"9688_CR40","first-page":"831","volume":"65","author":"SI Ikeda","year":"2013","unstructured":"Ikeda SI (2013) Cerebral amyloid angiopathy with familial transthyretin-derived oculoleptomeningeal amyloidosis. Brain Nerve 65:831\u2013842","journal-title":"Brain Nerve"},{"key":"9688_CR41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Conceicao","year":"2016","unstructured":"Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L (2016) \"Red-flag\" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 21:5\u20139","journal-title":"J Peripher Nerv Syst"},{"key":"9688_CR42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","volume":"21","author":"A Carvalho","year":"2015","unstructured":"Carvalho A, Rocha A, Lobato L (2015) Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 21:282\u2013292","journal-title":"Liver Transpl"},{"key":"9688_CR43","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","volume":"113","author":"NM Fine","year":"2014","unstructured":"Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M (2014) Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol 113:1723\u20131727","journal-title":"Am J Cardiol"},{"key":"9688_CR44","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412","journal-title":"Circulation"},{"key":"9688_CR45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jcmg.2011.03.016","volume":"4","author":"C Rapezzi","year":"2011","unstructured":"Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, Ferlini A, Longhi S, Lorenzini M, Reggiani LB, Gagliardi C, Gallo P, Villani C, Salvi F (2011) Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imag 4:659\u2013670","journal-title":"JACC Cardiovasc Imag"},{"key":"9688_CR46","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10072-012-1105-y","volume":"34","author":"M Luigetti","year":"2013","unstructured":"Luigetti M, Conte A, Del Grande A, Bisogni G, Madia F, Lo Monaco M, Laurenti L, Obici L, Merlini G, Sabatelli M (2013) TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci 34:1057\u20131063","journal-title":"Neurol Sci"},{"key":"9688_CR47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","volume":"69","author":"V Plante-Bordeneuve","year":"2007","unstructured":"Plante-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G (2007) Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69:693\u2013698","journal-title":"Neurology"},{"key":"9688_CR48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/13506120903421850","volume":"16","author":"B Do Amaral","year":"2009","unstructured":"Do Amaral B, Coelho T, Sousa A, Guimaraes A (2009) Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type. Amyloid 16:232\u2013238","journal-title":"Amyloid"},{"key":"9688_CR49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","volume":"82","author":"GJ Ebenezer","year":"2017","unstructured":"Ebenezer GJ, Liu Y, Judge DP, Cunningham K, Truelove S, Carter ND, Sebastian B, Byrnes K, Polydefkis M (2017) Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol 82:44\u201356","journal-title":"Ann Neurol"},{"key":"9688_CR50","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.25433","volume":"85","author":"CC Chao","year":"2019","unstructured":"Chao CC, Hsueh HW, Kan HW, Liao CH, Jiang HH, Chiang H, Lin WM, Yeh TY, Lin YH, Cheng YY, Hsieh ST (2019) Skin nerve pathology: biomarkers of premanifest and manifest amyloid neuropathy. Ann Neurol 85:560\u2013573","journal-title":"Ann Neurol"},{"key":"9688_CR51","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","volume":"260","author":"MF Dohrn","year":"2013","unstructured":"Dohrn MF, Rocken C, De Bleecker JL, Martin JJ, Vorgerd M, Van den Bergh PY, Ferbert A, Hinderhofer K, Schroder JM, Weis J, Schulz JB, Claeys KG (2013) Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 260:3093\u20133108","journal-title":"J Neurol"},{"key":"9688_CR52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, Anan I, Karling P, Suhr OB (2014) THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis 9:61","journal-title":"Orphanet J Rare Dis"},{"key":"9688_CR53","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.0954-6820.1983.tb08613.x","volume":"214","author":"L Steen","year":"1983","unstructured":"Steen L, Ek B (1983) Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms. Acta Med Scand 214:387\u2013397","journal-title":"Acta Med Scand"},{"key":"9688_CR54","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","volume":"235","author":"O Suhr","year":"1994","unstructured":"Suhr O, Danielsson A, Holmgren G, Steen L (1994) Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 235:479\u2013485","journal-title":"J Intern Med"},{"key":"9688_CR55","first-page":"1","volume":"590","author":"R Andersson","year":"1976","unstructured":"Andersson R (1976) Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden. Acta Med Scand Suppl 590:1\u201364","journal-title":"Acta Med Scand Suppl"},{"key":"9688_CR56","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/ajt.13755","volume":"16","author":"MY Bechiri","year":"2016","unstructured":"Bechiri MY, Eliahou L, Rouzet F, Fouret PJ, Antonini T, Samuel D, Adam R, Adams D, Slama MS, Algalarrondo V (2016) Multimodality imaging of cardiac transthyretin amyloidosis 16 years after a domino liver transplantation. Am J Transplant 16:2208\u20132212","journal-title":"Am J Transplant"},{"key":"9688_CR57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/bjo.81.4.295","volume":"81","author":"E Ando","year":"1997","unstructured":"Ando E, Ando Y, Okamura R, Uchino M, Ando M, Negi A (1997) Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Br J Ophthalmol 81:295\u2013298","journal-title":"Br J Ophthalmol"},{"key":"9688_CR58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/eye.2013.217","volume":"28","author":"T Liu","year":"2014","unstructured":"Liu T, Zhang B, Jin X, Wang W, Lee J, Li J, Yuan H, Cheng X (2014) Ophthalmic manifestations in a Chinese family with familial amyloid polyneuropathy due to a TTR Gly83Arg mutation. Eye 28:26\u201333","journal-title":"Eye"},{"key":"9688_CR59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","volume":"22","author":"JM Beirao","year":"2015","unstructured":"Beirao JM, Malheiro J, Lemos C, Beirao I, Costa P, Torres P (2015) Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases. Amyloid 22:117\u2013122","journal-title":"Amyloid"},{"key":"9688_CR60","first-page":"282405","volume":"2015","author":"AC Martins","year":"2015","unstructured":"Martins AC, Rosa AM, Costa E, Tavares C, Quadrado MJ, Murta JN (2015) Ocular manifestations and therapeutic options in patients with familial amyloid polyneuropathy: a systematic review. BioMed Res Int 2015:282405","journal-title":"BioMed Res Int"},{"key":"9688_CR61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.49.1.229","volume":"49","author":"PJ Dyck","year":"1997","unstructured":"Dyck PJ, Davies JL, Litchy WJ, O'Brien PC (1997) Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49:229\u2013239","journal-title":"Neurology"},{"key":"9688_CR62","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s00415-007-0617-5","volume":"254","author":"C Denier","year":"2007","unstructured":"Denier C, Ducot B, Husson H, Lozeron P, Adams D, Meyer L, Said G, Plant\u00e9-Bordeneuve V (2007) A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy. J Neurol 254:1684\u20131688","journal-title":"J Neurol"},{"key":"9688_CR63","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/jns.12120","volume":"20","author":"MHJ Pruppers","year":"2015","unstructured":"Pruppers MHJ, Merkies ISJ, Faber CG, Da Silva AM, Costa V, Coelho T (2015) The Val30Met familial amyloid polyneuropathy specific Rasch-built overall disability scale (FAP-RODS\u00a9). J Peripher Nerv Syst 20:319\u2013327","journal-title":"J Peripher Nerv Syst"},{"key":"9688_CR64","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2012.10.013","volume":"87","author":"DM Sletten","year":"2012","unstructured":"Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W (2012) COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 87:1196\u20131201","journal-title":"Mayo Clin Proc"},{"key":"9688_CR65","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39:2799\u20132806","journal-title":"Eur Heart J"},{"key":"9688_CR66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","volume":"19","author":"EJ Vinik","year":"2014","unstructured":"Vinik EJ, Vinik AI, Paulson JF, Merkies IS, Packman J, Grogan DR, Coelho T (2014) Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst 19:104\u2013114","journal-title":"J Peripher Nerv Syst"},{"key":"9688_CR67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"issue":"3","key":"9688_CR68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.nmd.2018.11.002","volume":"29","author":"GL Vita","year":"2018","unstructured":"Vita GL, Stancanelli C, Gentile L, Barcellona C, Russo M, Bella GD, Vita G, Mazzeo A (2018) 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR). Neuromuscul Disord 29(3):213\u2013220","journal-title":"Neuromuscul Disord"},{"key":"9688_CR69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(99)00231-2","volume":"171","author":"K Tashima","year":"1999","unstructured":"Tashima K, Ando Y, Terazaki H, Yoshimatsu S-i, Suhr OB, Obayashi K, Yamashita T, Ando E, Uchino M, Ando M (1999) Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 171:19\u201323","journal-title":"J Neurol Sci"},{"key":"9688_CR70","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mus.25563","volume":"56","author":"PJ Dyck","year":"2017","unstructured":"Dyck PJ, Kincaid JC, Dyck PJB, Chaudhry V, Goyal NA, Alves C, Salhi H, Wiesman JF, Labeyrie C, Robinson-Papp J, Cardoso M, Laura M, Ruzhansky K, Cortese A, Brannagan TH 3rd, Khoury J, Khella S, Waddington-Cruz M, Ferreira J, Wang AK, Pinto MV, Ayache SS, Benson MD, Berk JL, Coelho T, Polydefkis M, Gorevic P, Adams DH, Plante-Bordeneuve V, Whelan C, Merlini G, Heitner S, Drachman BM, Conceicao I, Klein CJ, Gertz MA, Ackermann EJ, Hughes SG, Mauermann ML, Bergemann R, Lodermeier KA, Davies JL, Carter RE, Litchy WJ (2017) Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. Muscle Nerve 56:901\u2013911","journal-title":"Muscle Nerve"},{"key":"9688_CR71","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/WCO.0000000000000476","volume":"30","author":"D Adams","year":"2017","unstructured":"Adams D, Cauquil C, Labeyrie C (2017) Familial amyloid polyneuropathy. Curr Opin Neurol 30:481\u2013489","journal-title":"Curr Opin Neurol"},{"key":"9688_CR72","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","volume":"78","author":"LL Mariani","year":"2015","unstructured":"Mariani LL, Lozeron P, Theaudin M, Mincheva Z, Signate A, Ducot B, Algalarrondo V, Denier C, Adam C, Nicolas G, Samuel D, Slama MS, Lacroix C, Misrahi M, Adams D (2015) Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901\u2013916","journal-title":"Ann Neurol"},{"key":"9688_CR73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"9688_CR74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"9688_CR75","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","volume":"29","author":"L Obici","year":"2016","unstructured":"Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, Kyriakides T, European Network for T-F (2016) Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Curr Opin Neurol 29(Suppl 1):S27\u2013S35","journal-title":"Curr Opin Neurol"},{"key":"9688_CR76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/13506129.2014.941463","volume":"21","author":"M Theaudin","year":"2014","unstructured":"Theaudin M, Cauquil C, Antonini T, Algalarrondo V, Labeyrie C, Aycaguer S, Clement M, Kubezyk M, Nonnez G, Morier A, Bourges C, Darras A, Mouzat L, Adams D (2014) Familial amyloid polyneuropathy: elaboration of a therapeutic patient education programme, \"EdAmyl\". Amyloid 21:225\u2013230","journal-title":"Amyloid"},{"key":"9688_CR77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1080\/13506120802676948","volume":"16","author":"E Dardiotis","year":"2009","unstructured":"Dardiotis E, Koutsou P, Papanicolaou EZ, Vonta I, Kladi A, Vassilopoulos D, Hadjigeorgiou G, Christodoulou K, Kyriakides T (2009) Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid 16:32\u201337","journal-title":"Amyloid"},{"key":"9688_CR78","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.21902","volume":"54","author":"II van Gameren","year":"2006","unstructured":"van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH (2006) Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 54:2015\u20132021","journal-title":"Arthritis Rheum"},{"key":"9688_CR79","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/ajkd.1998.v31.pm9631837","volume":"31","author":"L Lobato","year":"1998","unstructured":"Lobato L, Beirao I, Guimaraes SM, Droz D, Guimaraes S, Grunfeld JP, Noel LH (1998) Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits. Am J Kidney Dis 31:940\u2013946","journal-title":"Am J Kidney Dis"},{"key":"9688_CR80","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","volume":"18","author":"L Lobato","year":"2003","unstructured":"Lobato L, Beirao I, Silva M, Bravo F, Silvestre F, Guimaraes S, Sousa A, Noel LH, Sequeiros J (2003) Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. Nephrol Dial Transplant 18:532\u2013538","journal-title":"Nephrol Dial Transplant"},{"key":"9688_CR81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13506120600722662","volume":"13","author":"K Oguchi","year":"2006","unstructured":"Oguchi K, Takei Y, Ikeda S (2006) Value of renal biopsy in the prognosis of liver transplantation in familial amyloid polyneuropathy ATTR Val30Met patients. Amyloid 13:99\u2013107","journal-title":"Amyloid"},{"key":"9688_CR82","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/ndt\/gfh063","volume":"19","author":"R Snanoudj","year":"2004","unstructured":"Snanoudj R, Durrbach A, Gauthier E, Adams D, Samuel D, Ferlicot S, Bedossa P, Prigent A, Bismuth H, Charpentier B (2004) Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. Nephrol Dial Transplant 19:1779\u20131785","journal-title":"Nephrol Dial Transplant"},{"key":"9688_CR83","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Plante-Bordeneuve V, Rapezzi C, Said G, Salvi F (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8:31","journal-title":"Orphanet J Rare Dis"},{"key":"9688_CR84","first-page":"195","volume":"68","author":"CJ Klein","year":"2011","unstructured":"Klein CJ, Vrana JA, Theis JD, Dyck PJ, Dyck PJ, Spinner RJ, Mauermann ML, Bergen HR 3rd, Zeldenrust SR, Dogan A (2011) Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 68:195\u2013199","journal-title":"Arch Neurol"},{"issue":"Suppl 1","key":"9688_CR85","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T, European Network for T-F (2016) First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 29(Suppl 1):S14\u2013S26","journal-title":"Curr Opin Neurol"},{"key":"9688_CR86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","volume":"76","author":"SI van Nes","year":"2011","unstructured":"van Nes SI, Vanhoutte EK, van Doorn PA, Hermans M, Bakkers M, Kuitwaard K, Faber CG, Merkies IS (2011) Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76:337\u2013345","journal-title":"Neurology"},{"key":"9688_CR87","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s00259-018-3963-x","volume":"45","author":"E Piekarski","year":"2018","unstructured":"Piekarski E, Chequer R, Algalarrondo V, Eliahou L, Mahida B, Vigne J, Adams D, Slama MS, Le Guludec D, Rouzet F (2018) Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers. Eur J Nucl Med Mol Imaging 45:1108\u20131118","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9688_CR88","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","volume":"7","author":"S Yamamoto","year":"2007","unstructured":"Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, Gjertsen H, Soderdahl G, Wikstrom L, Ando Y, Suhr OB, Ericzon BG (2007) Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 7:2597\u20132604","journal-title":"Am J Transplant"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09688-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-019-09688-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09688-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T10:08:27Z","timestamp":1622887707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-019-09688-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["9688"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09688-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This review was sponsored by the Amyloidosis Research Consortium. Dr Adams reports grants from Alnylam and Pfizer and personal fees from Prothena, GSK, Alnylam, and Pfizer. Dr Ando has nothing to disclose. Dr Beir\u00e3o has nothing to disclose. Dr Coelho was paid per protocol for clinical trials from FoldRx, Pfizer, Ionis, and Alnylam and received grants from FoldRx and Pfizer; received support from Pfizer, Ionis, Biogen, and Alnylam to attend scientific meetings; and has presented on behalf of Pfizer, Alnylam, GSK, Prothena, and Ionis\/Akcea and received honoraria. Dr Gertz has received personal fees from Ionis\/Akcea, Alnylam, Prothena, Celgene, Janssen, Annexon, Appellis, Amgen, Medscape, Physicians Education Resource, and Research to Practice; grants and personal fees from Spectrum; personal fees for Data Safety Monitoring board from AbbVie; speaker fees from Teva, Johnson and Johnson, Medscape, and DAVA Oncology; royalties from Springer Publishing; and grant funding from the Amyloidosis Foundation, the International Waldenstr\u00f6m Foundation, and the National Cancer Institute (SPORE MM SPORE 5P50 CA186781-04). In addition, he has served on advisory boards for Pharmacyclics and for Proclara (outside the submitted work). Dr Gillmore has participated in advisory boards for Alnylam Pharmaceuticals Inc and GSK Inc. Dr Hawkins has nothing to disclose. Ms Lousada has received honoraria from Akcea. Dr Suhr has received honoraria and travel and consultancy fees from Ionis\/Akcea, Alnylam, Prothena, and Intellia. Dr Merlini has received honoraria from Janssen and Prothena; travel support from Prothena and Celgene; and consulting fees from Millennium, Pfizer, Janssen, Prothena, and Ionis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable for this type of study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Not applicable for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}